Goals for AACR
My aspirational goal for AACR is to continue to support and promote innovative science across the spectrum from discovery to clinical translation. I also think it is imperative for AACR to continue to support the next generation of scientific leaders, including trainees and junior faculty, through innovative programs, mentoring initiatives, and support for career development for young investigators, especially in the current climate. I have contributed to many different initiatives of importance to our field, including in my institutional role as senior vice president for translational research at MSK, as a laboratory PI and physician scientist, and as a long-standing AACR member and program chair and director of the AACR Molecular Biology in Clinical Oncology course. Through leadership in translational cancer science, mentorship, and collaborative research, I hope to help AACR accelerate progress against all cancers.
Research Interests
Leukemia; hematologic malignancies; genomics; epigenetics; targeted therapy; in vivo models; functional genomics; clonal hematopoiesis.
Current Affiliations
Senior vice president, attending physician, and professor, medicine, Weill Cornell Medical College, New York, New York.
Previous Positions
Deputy physician-in-chief, translational research, Memorial Hospital, New York, New York (2022-2024); chief, molecular cancer medicine service, HOPP, New York, New York (2019-2022); director, Center for Hematologic Malignancies, New York, New York (2016-2019); associate professor, medicine (2011-2015) and assistant professor (2007-2011), Weill Cornell Medical College, New York, New York; associate attending physician (2011-2014), assistant member (2007-2011), and assistant attending physician (2007-2011), Memorial Sloan Kettering Cancer Center, New York, New York; instructor, Dana Farber Cancer Institute, Boston, Massachusetts (2006-2007).
Education
MD, Johns Hopkins University School of Medicine, Baltimore, Maryland (1999); AB, biology, Harvard College, Cambridge, Massachusetts (1994).
Postdoctoral Training
Postdoctoral fellow, Brigham and Women’s Hospital/Harvard Medical School (2003-2007), Cambridge, Massachusetts; fellow, hematology/medical oncology, Dana Farber Cancer Institute/Partners Cancer Care (2002-2006), Boston, Massachusetts; intern and resident, internal medicine, Massachusetts General Hospital (1999-2002), Boston, Massachusetts; research training fellow, Johns Hopkins University School of Medicine (1997-1999), Baltimore, Maryland; undergraduate research assistant, Brigham and Women’s Hospital/Harvard Medical School (1991-1994), Cambridge, Massachusetts.
Selected AACR Service, Honors, and Awards
Co-Editor-in-Chief, Blood Cancer Discovery (2026-2030); chair, AACR Molecular Biology in Clinical Oncology Workshop (2025-2026); member, AACR Scientific Advisory Council (2025-2027); member, AACR Hematologic Malignancies Working Group Steering Committee (2024-2027); cochair, AACR Annual Meeting Program Committee (2017-2018); chair, AACR Annual Meeting Education Committee (2017-2018); member, AACR Annual Meeting Clinical Trials Committee (2015-2017); cochair, “Role of JAK-STAT Pathway Activation in MPN Pathogenesis and Therapeutic Response”, JCA-AACR Joint Conference on Hematologic Malignancies (2016); cochair, AACR Annual Meeting Program Committee (2015-2016); deputy editor, Clinical Cancer Research (2011-2019).
Selected Honors, Awards, and Non-AACR Service
Recipient, Excellence in Scientific Service, Leukemia and Lymphoma Society (2023); member, scientific advisory board, Mission Bio (2020-present); member, scientific advisory board, Prelude Therapeutics (2020-present); founder, member, scientific advisory board and member, board of directors, Ajax Therapeutics (2019-present); founder and member, scientific advisory board, Auron Therapeutics (2018-present); member, scientific advisory board, Zentalis (2018-present); recipient, William Dameshek Prize, American Society of Hematology (2018); member, board of directors, and member, scientific advisory board, The Mark Foundation for Cancer Research (2017-present); member, scientific advisory board, MPN Research Foundation (2017-present); member, supervisory board, Qiagen (2016-present); member, scientific advisory board, C4 Therapeutics (2016-2024); member, scientific advisory board, Imago (2016-2023); member (2015-2017) and chair (2017-2019), Cancer Biomarkers Study Section, National Cancer Institute; member, scientific advisory board, Isoplexis (2014-present); member, scientific advisory board, Leukemia and Lymphona Society TAP Program (2013-2019); member, scientific advisory board, Loxo Therapeutics (2013-2019); recipient, Boyer Award for Clinical Research, Memorial Sloan Kettering Cancer Center (2011); recipient, Young Investigator Award, American Society of Clinical Oncology (2006); recipient, Basic Research Fellow Award, American Society of Hematology (2006).